On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.

On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.